



# BioAmpDiagnostics

*“Actionable Results Before Antibiotic Prescribing”*



**[www.bioampdx.com](http://www.bioampdx.com)**



**[tdeboer@bioampdx.com](mailto:tdeboer@bioampdx.com)**

# BioAmp Team — Together we are working to combat antibiotic resistance through diagnostic innovation



Tara deBoer, Ph.D.  
*Inventor of Core Tech*



Angel Resendez, Ph.D.  
(Head Chemist)  
Deep chemistry expertise



Aubrianne Milton, B.S.  
(Research Associate)  
Chemistry & Biochemistry



Isha Kane, B.S.  
(Lab Coordinator)  
Scientific & Admin

## BioAmp Advisors (Business Support):




Kelly Gardner,  
Ph.D., MBA  
(Successful Exit)



Kevin Krause,  
MBA.  
(AMR-UTIs, BD)  
ACHAAGEN  
AN2 Therapeutics



Dr. Bradley Frazee  
(ED MD, ID)



Danka-Florence  
Petrovic (CLS)



Prof. Lee Riley  
(UTIs & AMR)



# Antibiotic Resistance Impacts Many Conditions:

BioAmp is first working to direct care of high-risk UTIs (cUTIs)



**2 M**

## High-Risk UTIs (cUTIs)

Patients: Males, pyelonephritis, & immunocompromised



**400,000 hospitalizations**  
(increased by 50% over 10 yrs)<sup>1</sup>

+

**1/2**

**Bloodstream Infections**  
originate from a UTI<sup>2</sup>



**72-96 h** to define appropriate treatment

Putting patients at risk of:



Treatment Failure



Disease Progression




Co-Morbidity/Mortality

# Diagnostic Standard is Microbiology

Slow time to results leads to poor outcomes for patients

## STANDARD OF CARE:

Manual Clinical Microbiology



Time to Diagnosis: **DAYS**  
72-96 h

## BioAmp is TRANSFORMING

Standard of care towards automation



Time to Diagnosis: **MINUTES**  
15 min


 BioAmp is delivering results in **MINUTES** instead of DAYS, so that patients can feel better immediately



# We Apply a Non-Growth Method to Deliver Results in Minutes


- Simple color-changing signal technology

## STANDARD OF CARE: Clinical Microbiology



Detection method: **bacterial growth**

## BioAmpDiagnostics



Detection method: **colorimetric**

# Results Delivered in Minutes will Make All the Difference — Helping physicians treat patients with the right antibiotic immediately



**Expediting** time to  
appropriate treatment



**Decreasing**  
mortality rates




**Shortening**  
hospital LOS



15 min




=



Drug **SUSCEPTIBLE**  
infection






=



Drug **RESISTANT**  
infection

# BioAmp Harnesses an Amplification Strategy — DETECT (Dual-Enzyme Trigger-Enable Cascade Technology)



BioAmp circumvents the need for bacterial growth by **amplifying** the presence of **low-abundant** biomarkers

# BioAmp Stands Apart from Competitors — Delivering results 288 X faster than the standard of care




- ✓ Simple and scalable technology
- ✓ Can be adapted to existing tools & instruments already found in clinical laboratories
- ✓ **Limit of Detection 100X** better than all competitors

Post-growth →

Minutes

+3h

+24 h



**Agar  
72 HOURS**

BioAmpDiagnostics

**288 X faster**

**FIRST LIGHT  
DIAGNOSTICS**

**Roche GeneWEAVE™**

**GENEFLUIDICS**

**ACCELERATE  
DIAGNOSTICS™**



✓ All Require Sophisticated Instrumentation



# Approach Validated by Targeting Antibiotic Resistance Biomarkers in Urine Samples — Tested 452 clinical urine samples



- ✓ **IRB-Approved Study, double blinded -**  
Highland Hospital (Oakland, CA), public hospital
- ✓ **Diverse patient population:**  
wide socioeconomic backgrounds
- ✓ **Comparator - clinical microbiology**  
(**GOLD STANDARD**)
- ✓ **No samples excluded**

Company	Test	Sensitivity	Specificity	NPV	FDA Cleared	CE Mark
BioAmpDiagnostics	<b>DETECT</b>	<b>91%</b>	<b>97%</b>	<b>99.8%</b>		
 <b>BACTERIO SCAN</b> Detection. Diagnosis. Decisions.	216Dx	97.7%	72.1%	99.2%	✗	
 <b>GENE FLUIDICS</b>	UTiMax	92%	97%	81%		✗



# Overcoming Barriers of Market Entry —

## We are building a secondary reagent test that fits existing hardware



Test to be run on existing automated chemistry analyzers:



### Sales

Combo of direct sales to hospitals (clinical lab) & partnerships with analyzer manufactures



### Test sell price

\$119 (price validation, existing equiv. test \$110/test)



### Reimbursement

Existing CPT Codes (\$239 reimbursement)



### Profit

To hospital (clinical lab)



### Margins

Opportunity for margins > 90%



### Direct Regulatory Path

510(k) Clearance

# BioAmp's technology can be fitted to multiple test formats

**\$ 4 B**


Clinical Microbiology  
Market

**77 %**


Market shared across  
20 companies

**45 %**

US Market  
Segment



# Traction & Emerging Milestones



## PRE-SEED ROUND (Convertible Note, \$600K - *matching*):

- ✓ Translating current assay format to target product form - secondary reagent test
- ✓ Preparing health economic studies to address key adoption & implementation risks
- ✓ Preparing for FDA pre-submission



**Product Launch  
2023**